US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 2A.
- Target
- 5-hydroxytryptamine receptor 2A
- Mechanism
- Serotonin 2c (5-HT2c) receptor antagonist
pharma · Fibromyalgia · Primary Fibromyalgia · TNXP
Tonix Pharmaceuticals Holding
Tonix Pharmaceuticals Holding drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
200 Connell Dr, Berkeley Heights, New Jersey 07922, US HQ
2007 Founded
154 Employees
Public company Type
TNXP · NYSE Ticker
Company details
- Status
- Public
- HQ
- 200 Connell Dr, Berkeley Heights, New Jersey 07922, US
- Founded
- 2007
- Employees
- 154
- Programs
- 4
- Drugs
- 4
- Patents
- 16
Tonix Pharmaceuticals Holding pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Tonix Pharmaceuticals Holding drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Oxytocin receptor.
- Target
- Oxytocin receptor
- Mechanism
- Oxytocin receptor agonist
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 1B.
- Target
- 5-hydroxytryptamine receptor 1B
- Mechanism
- Serotonin 1d (5-HT1d) receptor agonist
-
US regulatory status: approved. Molecular target: Vasopressin receptor.
- Target
- Vasopressin receptor
- Mechanism
- Vasopressin receptor agonist